Figure 10. Effect of metformin, nifedipine, MCC950, and anakinra treatment on Tet2-deficient myeloid cells.

(A) Representative flow cytometry plots of donor chimerism (CD45.1⁺/CD45.2⁺) in the PB of recipient mice after 30 days of the indicated drug treatment and quantification of CD45.1⁺ cells in the PB, CD45.2⁺ cells in the PB, CD45.1⁺ cells in the BM, CD45.2⁺ cells in the BM, CD45.1⁺ cells in the spleen, and CD45.2⁺ cells in the spleen after 30 days of the indicated drug treatment. (B) Representative flow cytometry profile of myeloid cells (Gr-1⁺CD11b⁺) in the PB of recipient mice after 30 days of the indicated drug treatment and quantification of Gr-1⁺CD11b⁺ double-positive cells in the PB, BM, and spleen after 30 days of the indicated drug treatment (n = 3–6 mice per group). Data are shown as the mean ± SEM. *P < 0.05, **P < 0.005, ***P < 0.0005, and ****P < 0.0001, by 1-way ANOVA.